371 related articles for article (PubMed ID: 11112236)
1. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy.
Douketis JD; Foster GA; Crowther MA; Prins MH; Ginsberg JS
Arch Intern Med; 2000 Dec 11-25; 160(22):3431-6. PubMed ID: 11112236
[TBL] [Abstract][Full Text] [Related]
2. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
3. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism.
Douketis JD; Gu CS; Schulman S; Ghirarduzzi A; Pengo V; Prandoni P
Ann Intern Med; 2007 Dec; 147(11):766-74. PubMed ID: 18056660
[TBL] [Abstract][Full Text] [Related]
4. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism.
Jiménez D; Díaz G; Marín E; Vidal R; Sueiro A; Yusen RD
Thromb Haemost; 2006 Mar; 95(3):562-6. PubMed ID: 16525588
[TBL] [Abstract][Full Text] [Related]
5. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
Marik PE; Cavallazzi R
PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
[TBL] [Abstract][Full Text] [Related]
6. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism.
Douketis JD; Kearon C; Bates S; Duku EK; Ginsberg JS
JAMA; 1998 Feb; 279(6):458-62. PubMed ID: 9466640
[TBL] [Abstract][Full Text] [Related]
7. Secondary prevention of venous thromboembolism: A role for low-molecular-weight heparin.
Monreal M; Roncales FJ; Ruiz J; Muchart J; Fraile M; Costa J; Hernandez JA
Haemostasis; 1998; 28(5):236-43. PubMed ID: 10420072
[TBL] [Abstract][Full Text] [Related]
8. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.
Prandoni P; Noventa F; Ghirarduzzi A; Pengo V; Bernardi E; Pesavento R; Iotti M; Tormene D; Simioni P; Pagnan A
Haematologica; 2007 Feb; 92(2):199-205. PubMed ID: 17296569
[TBL] [Abstract][Full Text] [Related]
9. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
Goodin S
Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
[TBL] [Abstract][Full Text] [Related]
10. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting.
Willey VJ; Bullano MF; Hauch O; Reynolds M; Wygant G; Hoffman L; Mayzell G; Spyropoulos AC
Clin Ther; 2004 Jul; 26(7):1149-59. PubMed ID: 15336480
[TBL] [Abstract][Full Text] [Related]
11. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis.
Mismetti P; Quenet S; Levine M; Merli G; Decousus H; Derobert E; Laporte S
Chest; 2005 Oct; 128(4):2203-10. PubMed ID: 16236875
[TBL] [Abstract][Full Text] [Related]
12. Treatment of DVT: how long is enough and how do you predict recurrence.
Agnelli G; Becattini C
J Thromb Thrombolysis; 2008 Feb; 25(1):37-44. PubMed ID: 17906973
[TBL] [Abstract][Full Text] [Related]
13. Duration of anticoagulation therapy for venous thromboembolism.
Bounameaux H; Perrier A
Hematology Am Soc Hematol Educ Program; 2008; ():252-8. PubMed ID: 19074092
[TBL] [Abstract][Full Text] [Related]
14. The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study.
Kyrle PA; Kammer M; Eischer L; Weltermann A; Minar E; Hirschl M; Heinze G; Eichinger S
J Thromb Haemost; 2016 Dec; 14(12):2402-2409. PubMed ID: 27696701
[TBL] [Abstract][Full Text] [Related]
15. Patients with a first symptomatic unprovoked deep vein thrombosis are at higher risk of recurrent venous thromboembolism than patients with a first unprovoked pulmonary embolism.
Kovacs MJ; Kahn SR; Wells PS; Anderson DA; Chagnon I; LE Gal G; Solymoss S; Crowther M; Perrier A; Ramsay T; Betancourt MT; White RH; Vickars L; Rodger MA
J Thromb Haemost; 2010 Sep; 8(9):1926-32. PubMed ID: 20561184
[TBL] [Abstract][Full Text] [Related]
16. Oral anticoagulant therapy in venous thromboembolism.
Cosmi B; Palareti G
Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
[TBL] [Abstract][Full Text] [Related]
17. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
[TBL] [Abstract][Full Text] [Related]
18. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.
; Büller HR; Gent M; Gallus AS; Ginsberg J; Prins MH; Baildon R
N Engl J Med; 1997 Sep; 337(10):657-62. PubMed ID: 9280815
[TBL] [Abstract][Full Text] [Related]
19. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
Hull RD; Pineo GF
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():11-23. PubMed ID: 15085462
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism.
Lecumberri R; Alfonso A; Jiménez D; Fernández Capitán C; Prandoni P; Wells PS; Vidal G; Barillari G; Monreal M;
Thromb Haemost; 2013 Oct; 110(4):834-43. PubMed ID: 23846721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
